MedTrace Logo

Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine

NCT02643446 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 809

Last updated 2017-08-01

No results posted yet for this study

Summary

The Purpose of this study is to assess the seroconversion using inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) sequential schedule in pilot areas where IPV was phased introduced into national immunization program (NIP) in China.

Conditions

  • Poliomyelitis

Interventions

BIOLOGICAL

IPV

IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4,group8 to group 11. IPV will be given at 3 month of age act as second vaccine in group 8,9,12

BIOLOGICAL

OPV

OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4,group 10 to group 11. OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7.

Sponsors & Collaborators

  • World Health Organization

    collaborator OTHER

  • Tianjin Center for Disease Control and Prevention

    collaborator UNKNOWN

  • Jilin Center for Disease Control and Prevention

    collaborator UNKNOWN

  • Hubei Provincial Center for Disease Control and Prevention

    collaborator OTHER

  • Guangdong Center for Disease Prevention and Control

    collaborator OTHER_GOV

  • Ningxia Center for Disease Control and Prevention

    collaborator UNKNOWN

  • Centers for Disease Control and Prevention, China

    lead OTHER_GOV

Principal Investigators

  • Huaqing Wang, MD, PhD · Centers for Disease Control and Prevention, China

  • Zhijie An, MD, MPH · Centers for Disease Control and Prevention, China

  • Zijian Feng, MD, MPH · Centers for Disease Control and Prevention, China

Eligibility

Min Age
2 Months
Max Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-03-31
Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02643446 on ClinicalTrials.gov